Viridian Therapeutics
VRDN
84 hedge funds and large institutions have $328M invested in Viridian Therapeutics in 2022 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 20 closing their positions.
55% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 20
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
15% more funds holding
Funds holding: 73 → 84 (+11)
5.11% more ownership
Funds ownership: 96.29% → 101.4% (+5.1%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
29% less capital invested
Capital invested by funds: $461M → $328M (-$134M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$10.1M |
| 3 |
CC
Commodore Capital
New York
|
+$9.24M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.59M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$19.2M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$10.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$6.06M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.7M |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.33M |
VRDN Hedge Fund Activity: Q2 2022 in Review
84 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2022, worth a combined $328M — down 29% from $461M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new VRDN positions and 20 closed out — a net gain of 11 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $17.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $19.2M sold.
- 84 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2022, up from 73 in Q1 2022.
- Funds reported $328M of Viridian Therapeutics stock for Q2 2022, down 29% quarter-over-quarter.
- 31 funds opened new Viridian Therapeutics positions in Q2 2022 and 20 closed out, a net change of +11 holders.
- The largest Viridian Therapeutics buyer in Q2 2022 was BlackRock, an estimated $17.1M added.
- The largest Viridian Therapeutics seller in Q2 2022 was Avidity Partners Management, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2022.